OTCPK:SHJBF (China)
Â
Class H
$
3.35
+0.35 (+11.67%)
08:08 PM EST
Business Description
Shanghai Junshi Biosciences Co Ltd
ISIN : CNE100003FF7
Share Class Description:
SHJBF: Class HTotal Employee Number:
2,903Compare
Compare
Traded in other countries / regions
01877.Hong Kong688180.ChinaSHJBF.USA8SJ.Germany IPO Date
2020-12-31Description
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.77 | |||||
Equity-to-Asset | 0.49 | |||||
Debt-to-Equity | 0.69 | |||||
Debt-to-EBITDA | -4.57 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.06 | |||||
Beneish M-Score | -2.44 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.7 | |||||
3-Year EBITDA Growth Rate | 37.7 | |||||
3-Year EPS without NRI Growth Rate | 28.3 | |||||
3-Year FCF Growth Rate | 18.9 | |||||
3-Year Book Growth Rate | -15.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 27.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 100 | |||||
9-Day RSI | 100 | |||||
14-Day RSI | 99.73 | |||||
3-1 Month Momentum % | 11.67 | |||||
6-1 Month Momentum % | 8.77 | |||||
12-1 Month Momentum % | 70.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.59 | |||||
Quick Ratio | 1.38 | |||||
Cash Ratio | 1.14 | |||||
Days Inventory | 395.05 | |||||
Days Sales Outstanding | 74.39 | |||||
Days Payable | 414.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.4 | |||||
Shareholder Yield % | -6.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 79.08 | |||||
Operating Margin % | -37 | |||||
Net Margin % | -33.65 | |||||
EBITDA Margin % | -36.49 | |||||
FCF Margin % | -51.29 | |||||
OCF Margin % | -20.5 | |||||
ROE % | -13.9 | |||||
ROA % | -7.29 | |||||
ROIC % | -10.11 | |||||
3-Year ROIIC % | 63.81 | |||||
ROC (Joel Greenblatt) % | -18.52 | |||||
ROCE % | -10.4 | |||||
Moat Score | 5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 6.67 | |||||
PB Ratio | 2.79 | |||||
Price-to-Tangible-Book | 2.86 | |||||
EV-to-EBIT | -35.25 | |||||
EV-to-Forward-EBIT | 196.11 | |||||
EV-to-EBITDA | -35.25 | |||||
EV-to-Forward-EBITDA | 3892.26 | |||||
EV-to-Revenue | 12.86 | |||||
EV-to-Forward-Revenue | 14.93 | |||||
EV-to-FCF | -25.06 | |||||
Price-to-GF-Value | 0.6 | |||||
Earnings Yield (Greenblatt) % | -2.84 | |||||
FCF Yield % | -3.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SHJBF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Junshi Biosciences Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 351.559 | ||
| EPS (TTM) ($) | -0.118 | ||
| Beta | 0.3183 | ||
| 3-Year Sharpe Ratio | 0.21 | ||
| 3-Year Sortino Ratio | 0.51 | ||
| Volatility % | 120.21 | ||
| 14-Day RSI | 99.73 | ||
| 14-Day ATR ($) | 0.001875 | ||
| 20-Day SMA ($) | 3.35 | ||
| 12-1 Month Momentum % | 70.05 | ||
| 52-Week Range ($) | 1.97 - 4.2285 | ||
| Shares Outstanding (Mil) | 1,025.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Junshi Biosciences Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Junshi Biosciences Co Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2024 | 2025-06-20 14:00 | 1.97 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-04-30 | 1.97 (+0.00%) | ||
| Annual report for 2024 | 2025-03-28 | 1.97 (+0.00%) | ||
| Third quarter earnings results for 2024 | 2024-10-28 | 1.24 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-08-30 | 1.50 (+0.00%) |
Show
Entries
Shanghai Junshi Biosciences Co Ltd Frequently Asked Questions
What is Shanghai Junshi Biosciences Co Ltd(SHJBF)'s stock price today?
The current price of SHJBF is $3.35. The 52 week high of SHJBF is $4.23 and 52 week low is $1.97.
When is next earnings date of Shanghai Junshi Biosciences Co Ltd(SHJBF)?
The next earnings date of Shanghai Junshi Biosciences Co Ltd(SHJBF) is .
Does Shanghai Junshi Biosciences Co Ltd(SHJBF) pay dividends? If so, how much?
Shanghai Junshi Biosciences Co Ltd(SHJBF) does not pay dividend.
Guru Commentaries on OTCPK:SHJBF
No articles.
Press Release
Articles on Shanghai Junshi Biosciences Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers